Cargando…
Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-base...
Autores principales: | Choi, Jae Hee, Geum, Min Jung, Kang, Ji Eun, Park, Nam Gi, Oh, Yun Kyoung, Rhie, Sandy Jeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620630/ https://www.ncbi.nlm.nih.gov/pubmed/34832982 http://dx.doi.org/10.3390/ph14111200 |
Ejemplares similares
-
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010) -
Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
por: Misaki, M., et al.
Publicado: (1998) -
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009) -
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010) -
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)